ANI PHARMACEUTICALS, INC Revenue
ANI PHARMACEUTICALS, INC (ANIP) reported Revenue of $266.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $266.04M, a 25.87% increase year-over-year.
- ANI PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $237.46M, a 20.46% increase year-over-year.
- ANI PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $247.06M, a 29.64% increase year-over-year.
- ANI PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $227.81M, a 53.58% increase year-over-year.
- ANI PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for fiscal 2025 was $883.37M, a 43.78% increase from fiscal 2024.
- ANI PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for fiscal 2024 was $614.38M, a 26.20% increase from fiscal 2023.
- ANI PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $486.82M, a 53.87% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $316.38M, a 46.38% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $266.04M 10-Q · filed 2026-08-07 | $503.51M 10-Q · filed 2026-08-07 | $750.57M derived: sum of 3 quarters · filed 2026-08-07 | $978.38M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $237.46M 10-Q · filed 2026-05-08 | $484.52M derived: sum of 2 quarters · filed 2026-05-08 | $712.34M derived: sum of 3 quarters · filed 2026-05-08 | $923.71M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $247.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $474.87M derived: sum of 2 quarters · filed 2026-02-27 | $686.24M derived: sum of 3 quarters · filed 2026-08-07 | $883.37M 10-K · filed 2026-02-27 |
| 2025-09-30 | $227.81M 10-Q · filed 2025-11-07 | $439.18M derived: sum of 2 quarters · filed 2026-08-07 | $636.31M 10-Q · filed 2025-11-07 | $826.88M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $211.37M 10-Q · filed 2026-08-07 | $408.49M 10-Q · filed 2026-08-07 | $599.07M derived: sum of 3 quarters · filed 2026-08-07 | $747.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $197.12M 10-Q · filed 2026-05-08 | $387.70M derived: sum of 2 quarters · filed 2026-05-08 | $536.03M derived: sum of 3 quarters · filed 2026-05-08 | $674.07M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $190.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $338.91M derived: sum of 2 quarters · filed 2026-02-27 | $476.95M derived: sum of 3 quarters · filed 2026-02-27 | $614.38M 10-K · filed 2026-02-27 |
| 2024-09-30 | $148.33M 10-Q · filed 2025-11-07 | $286.37M derived: sum of 2 quarters · filed 2025-11-07 | $423.80M 10-Q · filed 2025-11-07 | $555.46M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $138.04M 10-Q · filed 2025-08-08 | $275.47M 10-Q · filed 2025-08-08 | $407.12M derived: sum of 3 quarters · filed 2026-02-27 | $538.95M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $137.43M 10-Q · filed 2025-05-09 | $269.08M derived: sum of 2 quarters · filed 2026-02-27 | $400.91M derived: sum of 3 quarters · filed 2026-02-27 | $517.46M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $131.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $263.48M derived: sum of 2 quarters · filed 2026-02-27 | $380.03M derived: sum of 3 quarters · filed 2026-02-27 | $486.82M 10-K · filed 2026-02-27 |
| 2023-09-30 | $131.83M 10-Q · filed 2024-11-08 | $248.38M derived: sum of 2 quarters · filed 2024-11-08 | $355.16M 10-Q · filed 2024-11-08 | $449.39M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $116.55M 10-Q · filed 2024-08-06 | $223.33M 10-Q · filed 2024-08-06 | $317.56M derived: sum of 3 quarters · filed 2025-02-28 | $401.39M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $106.79M 10-Q · filed 2024-05-10 | $201.02M derived: sum of 2 quarters · filed 2025-02-28 | $284.84M derived: sum of 3 quarters · filed 2025-02-28 | $358.69M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $94.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $178.05M derived: sum of 2 quarters · filed 2025-02-28 | $251.91M derived: sum of 3 quarters · filed 2025-02-28 | $316.38M 10-K · filed 2025-02-28 |
| 2022-09-30 | $83.82M 10-Q · filed 2023-11-08 | $157.68M derived: sum of 2 quarters · filed 2023-11-08 | $222.15M 10-Q · filed 2023-11-08 | $283.08M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $73.86M 10-Q · filed 2023-08-09 | $138.33M 10-Q · filed 2023-08-09 | $199.26M derived: sum of 3 quarters · filed 2024-02-29 | $251.32M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $64.48M 10-Q · filed 2023-05-08 | $125.41M derived: sum of 2 quarters · filed 2024-02-29 | $177.47M derived: sum of 3 quarters · filed 2024-02-29 | $226.09M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $60.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $112.99M derived: sum of 2 quarters · filed 2024-02-29 | $161.62M derived: sum of 3 quarters · filed 2024-02-29 | $216.14M 10-K · filed 2024-02-29 |
| 2021-09-30 | $52.06M 10-Q · filed 2022-11-09 | $100.69M derived: sum of 2 quarters · filed 2022-11-09 | $155.21M 10-Q · filed 2022-11-09 | $212.46M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $48.63M 10-Q · filed 2022-08-08 | $103.15M 10-Q · filed 2022-08-08 | $160.40M derived: sum of 3 quarters · filed 2022-08-08 | $213.38M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $54.52M 10-Q · filed 2022-05-10 | $111.77M derived: sum of 2 quarters · filed 2022-05-10 | $164.75M derived: sum of 3 quarters · filed 2022-05-10 | $213.22M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $57.25M 10-K · filed 2021-03-11 | $110.23M derived: sum of 2 quarters · filed 2021-11-01 | $158.70M derived: sum of 3 quarters · filed 2021-11-01 | $208.47M 10-K · filed 2023-03-09 |
| 2020-09-30 | $52.98M 10-Q · filed 2021-11-01 | $101.45M derived: sum of 2 quarters · filed 2021-11-01 | $151.22M 10-Q · filed 2021-11-01 | $199.19M derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | $48.47M 10-Q · filed 2021-08-06 | $98.24M 10-Q · filed 2021-08-06 | $146.21M derived: sum of 3 quarters · filed 2021-08-06 | $197.55M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $49.77M 10-Q · filed 2021-05-07 | $97.74M derived: sum of 2 quarters · filed 2021-05-07 | $149.08M derived: sum of 3 quarters · filed 2021-05-07 | $203.43M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $47.97M 10-K · filed 2021-03-11 | $99.30M derived: sum of 2 quarters · filed 2021-03-11 | $153.66M derived: sum of 3 quarters · filed 2021-03-11 | $206.55M 10-K · filed 2022-03-15 |
| 2019-09-30 | $51.34M 10-K · filed 2021-03-11 | $105.69M derived: sum of 2 quarters · filed 2021-03-11 | $158.58M 10-Q · filed 2020-11-05 | $215.70M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $54.36M 10-K · filed 2021-03-11 | $107.24M 10-Q · filed 2020-08-06 | $164.37M derived: sum of 3 quarters · filed 2021-03-11 | $215.07M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $52.89M 10-K · filed 2021-03-11 | $110.01M derived: sum of 2 quarters · filed 2021-03-11 | $160.71M derived: sum of 3 quarters · filed 2021-03-11 | $207.98M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $57.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $107.83M derived: sum of 2 quarters · filed 2021-03-11 | $155.09M derived: sum of 3 quarters · filed 2021-03-11 | $201.58M 10-K · filed 2021-03-11 |
| 2018-09-30 | $50.70M 10-Q · filed 2019-11-06 | $97.97M derived: sum of 2 quarters · filed 2019-11-06 | $144.45M 10-Q · filed 2019-11-06 | $191.74M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $47.27M 10-Q · filed 2019-08-07 | $93.75M 10-Q · filed 2019-08-07 | $141.04M derived: sum of 3 quarters · filed 2020-02-27 | $189.20M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $46.48M 10-Q · filed 2019-05-09 | $93.77M derived: sum of 2 quarters · filed 2020-02-27 | $141.93M derived: sum of 3 quarters · filed 2020-02-27 | $186.70M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $47.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $95.45M derived: sum of 2 quarters · filed 2020-02-27 | $140.21M derived: sum of 3 quarters · filed 2020-02-27 | $176.84M 10-K · filed 2020-02-27 |
| 2017-09-30 | $48.16M 10-Q · filed 2018-11-06 | $92.93M derived: sum of 2 quarters · filed 2018-11-06 | $129.56M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $44.76M 10-Q · filed 2018-08-07 | $81.39M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $36.63M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | $128.62M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |